-
JP Morgan Lowers PT On Dendreon To $28
Thursday, August 4, 2011 - 6:21am | 26JP Morgan has lowered the price target on Dendreon (NASDAQ: DNDN) from $66 to $28 and maintains its Overweight rating.
-
Dendreon Withdraws Previous FY2011 Revenue Guidance of $350-400M; Expects Modest QoQ Growth
Wednesday, August 3, 2011 - 4:41pm | 50Dendreon (NASDAQ: DNDN) expects that adoption of the new reimbursement paradigm will take time. Accordingly, Dendreon is withdrawing its previous guidance of $350-400 million in revenue for 2011 and currently expects modest quarter over quarter revenue growth for the remainder of this year.
-
Onyx Pharmaceuticals and Multiple Myeloma Research Foundation Launch Carfilzomib Expanded Access Program
Wednesday, August 3, 2011 - 4:06pm | 101Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and the Multiple Myeloma Research Foundation today announced the initiation of an expanded access program for carfilzomib, a selective, next-generation proteasome inhibitor. The Carfilzomib Myeloma Access Program will include eligible patients in the...
-
Options Brief: Savient Pharmaceuticals
Wednesday, August 3, 2011 - 3:43pm | 82Shares of Savient Pharmaceuticals (NASDAQ: SVNT) are lower on the session by 1.96%, trading at $6.49. Overall put volume is now running at 6.24x the daily average, with 89% of all puts traded being purchases on the offer. 1,161 contracts have traded on the session so far. Savient Pharmaceuticals...
-
Biotech and Pharma News; BioSante Pharmaceuticals Closes $48.0 Million Public Offering of Common Stock
Wednesday, August 3, 2011 - 2:50pm | 1029LINCOLNSHIRE, Ill. - August 3, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the closing of its underwritten public offering of 16.0 million shares of common stock at a public offering price of $3.00 per share, for total gross proceeds of $48.0...
-
Options Brief: Sangamo BioSciences
Wednesday, August 3, 2011 - 2:19pm | 128Shares of Sangamo BioSciences (NASDAQ: SGMO) are lower on the session by 2.17%, trading at $4.97. Overall call volume is now running at 3.81x the daily average, with 86% of all calls traded being purchases on the offer. 1,279 contracts have traded on the session so far. Sangamo BioSciences, Inc...
-
LifeTech Capital Maintains Bionovo Strong Speculative Buy, Lowers PT
Wednesday, August 3, 2011 - 1:41pm | 73LifeTech Capital maintained its Bionovo (NASDAQ: BNVI) Strong Speculative Buy rating and lowered its Bionovo price target from $7.50 to $5 in a research report published today. In the report, LifeTech Capital states, "Menerba could become the first botanical blockbuster drug which we believe...
-
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-536 Program
Wednesday, August 3, 2011 - 8:16am | 124Acceleron Pharma, Inc. and Celgene Corporation (NASDAQ: CELG) today announced that the companies have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia. The companies already have a collaboration around sotatercept (ACE-011) entered in 2008....
-
Celsion Reaches Major Milestone With Enrollment of 600th Patient in Its Pivotal Phase III HEAT Study of ThermoDox in Primary Liver Cancer
Wednesday, August 3, 2011 - 8:09am | 148Celsion Corporation (NASDAQ: CLSN) today announced that it has reached its pre-planned enrollment objective of 600 patients in the Company's pivotal, Phase III HEAT study, a multinational, randomized, double-blind, placebo-controlled clinical trial of ThermoDox® in combination with radio frequency...
-
Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
Wednesday, August 3, 2011 - 8:05am | 139Neuralstem, Inc. (NYSE: CUR) announced it received a U.S. Department of Defense contract to develop its human neural stem cell technology for the treatment of cancerous brain tumors. The research contract, entitled "Research to Treat Cancerous Brain Tumors with Neural Stem Cells," will be carried...
-
Benzinga's Top Downgrades
Wednesday, August 3, 2011 - 7:58am | 127MetroPCS Communications Inc (NYSE: PCS) was downgraded by Robert W. Baird from "outperform" to "neutral." PCS' shares closed at $10.26 yesterday. PCS' trailing-twelve-month profit margin is 5.29%. Rodman & Renshaw downgraded Exact Sciences Corporation (NASDAQ: EXAS) from “market outperform” to...
-
A Peek Into The Market Before The Trading Starts
Wednesday, August 3, 2011 - 7:31am | 392Pre-open movers US stock futures are higher this morning, as investors are economic data and earnings from major companies. Futures for the Dow Jones Industrial Average surged 47 points to 11,851.00 and S&P 500 index futures rose 6.40 points to 1,253.70. Nasdaq 100 futures gained 10.00 points...
-
Sunesis Pharmaceuticals Issued U.S. Patent Covering Vosaroxin Use to Treat Leukemia
Wednesday, August 3, 2011 - 7:10am | 129Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,989,468 claiming methods of use for the Company's lead drug candidate, vosaroxin, at clinically relevant dose ranges and schedules, for the treatment of leukemia. The '...
-
Incyte Corporation Announces FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis
Wednesday, August 3, 2011 - 7:00am | 130Incyte Corporation (Nasdaq: INCY) announced today that the US Food and Drug Administration has accepted for filing the New Drug Application for Incyte's lead investigational compound, ruxolitinib (INCB18424/INC424), as a potential treatment for patients with myelofibrosis. MF is a potentially...
-
Rodman & Renshaw Downgrades Exact Sciences to Market Perform, Removes PT
Wednesday, August 3, 2011 - 2:48am | 63Rodman & Renshaw downgraded its rating on Exact Sciences (NASDAQ: EXAS) from Market Outperform to Market Perform. At the same time, the rating agency removed its price target on the company's stock. The previous price target was $7. On Tuesday, EXAS had a bad day as its shares lost 10.7% of...